Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics

Pharmacology and Therapeutics

Volumn 176, Issue , 2017, Pages 32-39

  Patel, Ravi B ^a   Vaduganathan, Muthiah ^a   Shah, Sanjiv J ^b   Butler, Javed ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; Heart failure; Mechanisms; Therapeutics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ANTICOAGULATION; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RHYTHM; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; HEART ATRIUM; HEART FAILURE; HEART STROKE VOLUME;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HEART ATRIA; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 85006241352     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.10.019     Document Type: Review

References (90)

1. Ambrosy, A.P., Fonarow, G.C., Butler, J., Chioncel, O., Greene, S.J., Vaduganathan, M.,.. Gheorghiade, M., The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63 (2014), 1123–1133.
2. Arora, R., Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: Implications for therapies targeting the atrial autonomic nervous system. Circ Arrhythm Electrophysiol 5 (2012), 850–859.
3. Barnes, J.L., Gorin, Y., Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 79 (2011), 944–956.
4. Beinart, R., Khurram, I.M., Liu, S., Yarmohammadi, H., Halperin, H.R., Bluemke, D.A.,.. Nazarian, S., Cardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm 10 (2013), 1325–1331.
5. Cadrin-Tourigny, J., Wyse, D.G., Roy, D., Blondeau, L., Levesque, S., Talajic, M.,.. Khairy, P., Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: A pooled analysis of AFFIRM and AF-CHF trials. J Cardiovasc Electrophysiol 25 (2014), 1306–1313.
6. Campbell, R.T., McMurray, J.J., Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Fail Clin 10 (2014), 481–501.
7. Cha, Y.M., Wokhlu, A., Asirvatham, S.J., Shen, W.K., Friedman, P.A., Munger, T.M.,.. Packer, D.L., Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: A comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol 4 (2011), 724–732.
8. Chen, C.L., Huang, S.K., Lin, J.L., Lai, L.P., Lai, S.C., Liu, C.W.,.. Lin, C.S., Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 45 (2008), 742–753.
9. Chugh, S.S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E.J.,.. Murray, C.J., Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation 129 (2014), 837–847.
10. Chung, M.K., Martin, D.O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C.A.,.. Van Wagoner, D.R., C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001), 2886–2891.
11. Connolly, S.J., Camm, A.J., Halperin, J.L., Joyner, C., Alings, M., Amerena, J.,.. Investigators, P., Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365 (2011), 2268–2276.
12. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A.,.. Investigators, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
13. Corley, S.D., Epstein, A.E., DiMarco, J.P., Domanski, M.J., Geller, N., Greene, H.L.,.. Investigators, A., Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004), 1509–1513.
14. Ducharme, A., Swedberg, K., Pfeffer, M.A., Cohen-Solal, A., Granger, C.B., Maggioni, A.P.,.. Investigators, C., Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 152 (2006), 86–92.
15. Edelmann, F., Musial-Bright, L., Gelbrich, G., Trippel, T., Radenovic, S., Wachter, R.,.. Project Multicenter Trials in the Competence Network Heart, F, Tolerability and feasibility of Beta-blocker titration in HFpEF versus HFrEF: Insights from the CIBIS-ELD Trial. JACC Heart Fail 4 (2016), 140–149.
16. Freed, B.H., Daruwalla, V., Cheng, J.Y., Aguilar, F.G., Beussink, L., Choi, A.,.. Shah, S.J., Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain. Circulation. Cardiovascular Imaging, 9, 2006, 10.1161/CIRCIMAGING.115.003754.
17. Friedrichs, K., Klinke, A., Baldus, S., Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 17 (2011), 556–563.
18. Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M.A., Maseri, A., Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997), 1180–1184.
19. Giugliano, R.P., Ruff, C.T., Braunwald, E., Murphy, S.A., Wiviott, S.D., Halperin, J.L.,.. Investigators, E.A.-T., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
20. Goldberger, J.J., Arora, R., Green, D., Greenland, P., Lee, D.C., Lloyd-Jones, D.M.,.. Shah, S.J., Evaluating the atrial myopathy underlying atrial fibrillation: Identifying the arrhythmogenic and thrombogenic substrate. Circulation 132 (2015), 278–291.
21. Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M.,.. Investigators, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
22. Hanna, N., Cardin, S., Leung, T.K., Nattel, S., Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 (2004), 236–244.
23. Hasenfuss, G., Pieske, B., Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34 (2002), 951–969.
24. Houser, S.R., Piacentino, V. 3rd, Weisser, J., Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32 (2000), 1595–1607.
25. Hunter, R.J., Liu, Y., Lu, Y., Wang, W., Schilling, R.J., Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. Circ Arrhythm Electrophysiol 5 (2012), 351–360.
26. January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C. Jr.,.. American College of Cardiology/American Heart Association Task Force on Practice, G, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–76.
27. Khand, A.U., Rankin, A.C., Martin, W., Taylor, J., Gemmell, I., Cleland, J.G., Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42 (2003), 1944–1951.
28. Kim, M.H., Johnston, S.S., Chu, B.C., Dalal, M.R., Schulman, K.L., Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 4 (2011), 313–320.
29. Kim, Y.M., Kattach, H., Ratnatunga, C., Pillai, R., Channon, K.M., Casadei, B., Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51 (2008), 68–74.
30. Kober, L., Torp-Pedersen, C., McMurray, J.J., Gotzsche, O., Levy, S., Crijns, H.,.. Dronedarone Study, G, Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008), 2678–2687.
31. Kong, M.H., Shaw, L.K., O'Connor, C., Califf, R.M., Blazing, M.A., Al-Khatib, S.M., Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?. Ann Noninvasive Electrocardiol 15 (2010), 209–217.
32. Kosmala, W., Holland, D.J., Rojek, A., Wright, L., Przewlocka-Kosmala, M., Marwick, T.H., Effect of If channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. Journal of the American College of Cardiology 62 (2013), 1330–1338.
33. Kotecha, D., Piccini, J.P., Atrial fibrillation in heart failure: What should we do?. Eur Heart J 36 (2015), 3250–3257.
34. Kotecha, D., Banerjee, A., Lip, G.Y., Increased stroke risk in atrial fibrillation patients with heart failure: Does ejection fraction matter?. Stroke 46 (2015), 608–609.
35. Kotecha, D., Holmes, J., Krum, H., Altman, D.G., Manzano, L., Cleland, J.G., Beta-Blockers in Heart Failure Collaborative, G. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. Lancet 384 (2014), 2235–2243.
36. Li, D., Fareh, S., Leung, T.K., Nattel, S., Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 100 (1999), 87–95.
37. Li, D., Shinagawa, K., Pang, L., Leung, T.K., Cardin, S., Wang, Z., Nattel, S., Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001), 2608–2614.
38. Ling, L.H., Kistler, P.M., Ellims, A.H., Iles, L.M., Lee, G., Hughes, G.L.,.. Taylor, A.J., Diffuse ventricular fibrosis in atrial fibrillation: Noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 60 (2012), 2402–2408.
39. Ling, L.H., Kistler, P.M., Kalman, J.M., Schilling, R.J., Hunter, R.J., Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 13 (2016), 131–147.
40. Machino-Ohtsuka, T., Seo, Y., Ishizu, T., Sugano, A., Atsumi, A., Yamamoto, M.,.. Aonuma, K., Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 62 (2013), 1857–1865.
41. Mamas, M.A., Caldwell, J.C., Chacko, S., Garratt, C.J., Fath-Ordoubadi, F., Neyses, L., A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 (2009), 676–683.
42. McCullough, P.A., Philbin, E.F., Spertus, J.A., Kaatz, S., Sandberg, K.R., Weaver, W.D., Resource Utilization Among Congestive Heart Failure, S, Confirmation of a heart failure epidemic: Findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 (2002), 60–69.
43. McMurray, J.J., Ezekowitz, J.A., Lewis, B.S., Gersh, B.J., van Diepen, S., Amerena, J.,.. Investigators, Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 6 (2013), 451–460.
44. Meisner, J.S., Keren, G., Pajaro, O.E., Mani, A., Strom, J.A., Frater, R.W.,.. Yellin, E.L., Atrial contribution to ventricular filling in mitral stenosis. Circulation 84 (1991), 1469–1480.
45. Melenovsky, V., Hwang, S.J., Lin, G., Redfield, M.M., Borlaug, B.A., Right heart dysfunction in heart failure with preserved ejection fraction. European Heart Journal 35 (2014), 3452–3462.
46. Melenovsky, V., Hwang, S.J., Redfield, M.M., Zakeri, R., Lin, G., Borlaug, B.A., Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circulation Heart Failure 8 (2015), 295–303.
47. Miyasaka, Y., Barnes, M.E., Gersh, B.J., Cha, S.S., Bailey, K.R., Abhayaratna, W.P.,.. Tsang, T.S., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006), 119–125.
48. Moe, G.W., Angus, C., Howard, R.J., Parker, T.G., Armstrong, P.W., Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res 26 (1992), 362–366.
49. Mozaffarian, D., Psaty, B.M., Rimm, E.B., Lemaitre, R.N., Burke, G.L., Lyles, M.F.,.. Siscovick, D.S., Fish intake and risk of incident atrial fibrillation. Circulation 110 (2004), 368–373.
50. Murdoch, C.E., Zhang, M., Cave, A.C., Shah, A.M., NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71 (2006), 208–215.
51. Narayan, S.M., Franz, M.R., Clopton, P., Pruvot, E.J., Krummen, D.E., Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 123 (2011), 2922–2930.
52. Nattel, S., Burstein, B., Dobrev, D., Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 1 (2008), 62–73.
53. Pages, G., Lenormand, P., L'Allemain, G., Chambard, J.C., Meloche, S., Pouyssegur, J., Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90 (1993), 8319–8323.
54. Pal, N., Sivaswamy, N., Mahmod, M., Yavari, A., Rudd, A., Singh, S.,.. Ashrafian, H., Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132 (2015), 1719–1725.
55. Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W.,.. Investigators, R.A., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
56. Pedersen, O.D., Bagger, H., Keller, N., Marchant, B., Kober, L., Torp-Pedersen, C., Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104 (2001), 292–296.
57. Reynolds, M.R., Outcomes with digoxin in atrial fibrillation: more data, no answers. J Am Coll Cardiol 64 (2014), 669–671.
58. Riegger, A.J., Liebau, G., The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (Lond) 62 (1982), 465–469.
59. Roy, D., Talajic, M., Nattel, S., Wyse, D.G., Dorian, P., Lee, K.L.,.. Congestive Heart Failure, I., Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008), 2667–2677.
60. Saba, S., Janczewski, A.M., Baker, L.C., Shusterman, V., Gursoy, E.C., Feldman, A.M.,.. London, B., Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 289 (2005), H1456–H1467.
61. Sakabe, M., Shiroshita-Takeshita, A., Maguy, A., Dumesnil, C., Nigam, A., Leung, T.K., Nattel, S., Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116 (2007), 2101–2109.
62. Sanders, P., Morton, J.B., Davidson, N.C., Spence, S.J., Vohra, J.K., Sparks, P.B., Kalman, J.M., Electrical remodeling of the atria in congestive heart failure: Electrophysiological and electroanatomic mapping in humans. Circulation 108 (2003), 1461–1468.
63. Sandhu, R.K., Hohnloser, S.H., Pfeffer, M.A., Yuan, F., Hart, R.G., Yusuf, S.,.. Healey, J.S., Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke 46 (2015), 667–672.
64. Santhanakrishnan, R., Wang, N., Larson, M.G., Magnani, J.W., McManus, D.D., Lubitz, S.A.,.. Ho, J.E., Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 (2016), 484–492.
65. Schneider, M.P., Hua, T.A., Bohm, M., Wachtell, K., Kjeldsen, S.E., Schmieder, R.E., Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55 (2010), 2299–2307.
66. Shah, S.J., Gheorghiade, M., Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300 (2008), 431–433.
67. Shannon, R.P., The relationship between altered load and impaired diastolic function in conscious dogs with pacing induced heart failure. Adv Exp Med Biol 346 (1993), 337–345.
68. Shiroshita-Takeshita, A., Brundel, B.J., Burstein, B., Leung, T.K., Mitamura, H., Ogawa, S., Nattel, S., Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74 (2007), 75–84.
69. Singh, B.N., Singh, S.N., Reda, D.J., Tang, X.C., Lopez, B., Harris, C.L.,.. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial, I, Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005), 1861–1872.
70. Spinale, F.G., Tomita, M., Zellner, J.L., Cook, J.C., Crawford, F.A., Zile, M.R., Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 261 (1991), H308–H318.
71. Spinale, F.G., Zellner, J.L., Johnson, W.S., Eble, D.M., Munyer, P.D., Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: Changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 28 (1996), 1591–1608.
72. Sridhar, A., Nishijima, Y., Terentyev, D., Khan, M., Terentyeva, R., Hamlin, R.L.,.. Carnes, C.A., Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res 84 (2009), 227–236.
73. Stambler, B.S., Fenelon, G., Shepard, R.K., Clemo, H.F., Guiraudon, C.M., Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 14 (2003), 499–507.
74. Stewart, S., Hart, C.L., Hole, D.J., McMurray, J.J., A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113 (2002), 359–364.
75. Suman-Horduna, I., Roy, D., Frasure-Smith, N., Talajic, M., Lesperance, F., Blondeau, L.,.. Investigators, A.-C.T., Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 61 (2013), 455–460.
76. Swedberg, K., Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Shi, H.,.. Investigators, E.-H.S., Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59 (2012), 1598–1603.
77. Vaduganathan, M., Michel, A., Hall, K., Mulligan, C., Nodari, S., Shah, S.J.,.. Gheorghiade, M., Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: A systematic review. Eur J Heart Fail 18 (2016), 54–65.
78. van Deursen, V.M., Urso, R., Laroche, C., Damman, K., Dahlstrom, U., Tavazzi, L.,.. Voors, A.A., Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 16 (2014), 103–111.
79. Van Gelder, I.C., Hagens, V.E., Bosker, H.A., Kingma, J.H., Kamp, O., Kingma, T.,.. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study, G, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002), 1834–1840.
80. Van Wagoner, D.R., Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 52 (2008), 306–313.
81. Wang, T.J., Larson, M.G., Levy, D., Vasan, R.S., Leip, E.P., Wolf, P.A.,.. Benjamin, E.J., Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation 107 (2003), 2920–2925.
82. Wang, Z., Zhang, Y., Gao, M., Wang, J., Wang, Q., Wang, X.,.. Hou, Y., Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy 31 (2011), 1051–1062.
83. Welles, C.C., Ku, I.A., Kwan, D.M., Whooley, M.A., Schiller, N.B., Turakhia, M.P., Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. J Am Coll Cardiol 59 (2012), 673–680.
84. Wijffels, M.C., Kirchhof, C.J., Dorland, R., Allessie, M.A., Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995), 1954–1968.
85. Wyse, D.G., Waldo, A.L., DiMarco, J.P., Domanski, M.J., Rosenberg, Y., Schron, E.B.,.. Atrial Fibrillation Follow-up Investigation of Rhythm Management, I, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002), 1825–1833.
86. Yang, S.S., Han, W., Zhou, H.Y., Dong, G., Wang, B.C., Huo, H.,.. Li, W.M., Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 121 (2008), 38–42.
87. Yeh, Y.H., Wakili, R., Qi, X.Y., Chartier, D., Boknik, P., Kaab, S.,.. Nattel, S., Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1 (2008), 93–102.
88. Zakeri, R., Chamberlain, A.M., Roger, V.L., Redfield, M.M., Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community based study. Circulation 128 (2013), 1085–1093.
89. Zhang, Y., Zhang, P., Mu, Y., Gao, M., Wang, J.R., Wang, Y.,.. Hou, Y.L., The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials. Clin Pharmacol Ther 88 (2010), 521–531.
90. Zou, Y., Komuro, I., Yamazaki, T., Kudoh, S., Aikawa, R., Zhu, W.,.. Yazaki, Y., Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ Res 82 (1998), 337–345.